Comparison of Subcellular Responses for the Evaluation and Prediction of the Chemotherapeutic Response to Cisplatin in Lung Adenocarcinoma using Raman Spectroscopy by Nawaz, Haq et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles Radiation and Environmental Science Centre 
2011-4 
Comparison of Subcellular Responses for the Evaluation and 
Prediction of the Chemotherapeutic Response to Cisplatin in Lung 
Adenocarcinoma using Raman Spectroscopy 
Haq Nawaz 
Technological University Dublin, haq.nawz@tudublin.ie 
Franck Bonnier 
Technological University Dublin, Franck.Bonnier@tudublin.ie 
Aidan Meade 
Technological University Dublin, aidan.meade@tudublin.ie 
Fiona Lyng 
Technological University Dublin, Fiona.lyng@tudublin.ie 
Hugh Byrne 
Technological University Dublin, hugh.byrne@tudublin.ie 
Follow this and additional works at: https://arrow.tudublin.ie/radart 
 Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, 
Biotechnology Commons, and the Medicinal Chemistry and Pharmaceutics Commons 
Recommended Citation 
Bonnier, F. et al (2011) Comparison of subcellular responses for the evaluation and prediction of the 
chemotherapeutic response to cisplatin in lung adenocarcinoma using Raman spectroscopy" Analyst, 
136, pp.2450-2463. doi:10.1039/c1an15104e 
This Article is brought to you for free and open access by 
the Radiation and Environmental Science Centre at 
ARROW@TU Dublin. It has been accepted for inclusion in 
Articles by an authorized administrator of ARROW@TU 
Dublin. For more information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
CREATED USING THE RSC ARTICLE TEMPLATE (VER. 3.1) - SEE WWW.RSC.ORG/ELECTRONICFILES FOR DETAILS 
ARTICLE TYPE www.rsc.org/xxxxxx  |  XXXXXXXX 
This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  1 
Comparison of subcellular responses for the evaluation and prediction 
of the chemotherapeutic response to cisplatin in lung adenocarcinoma 
using Raman spectroscopy 
 
Haq Nawaza*, Franck Bonnierb, Aidan D. Meadea,c Fiona M. Lynga, Hugh J. Byrneb  5 
 
aDIT Centre for Radiation and Environmental Science (RESC), Focas Research Institute, Dublin Institute of Technology, Kevin Street, 
Dublin 8, Ireland 
bFocas Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland 
cSchool of Physics, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland 10 
 
*Corresponding Author: Haq Nawaz, DIT Centre for Radiation and Environmental Science (RESC), Focas Research Institute, Dublin 
Institute of Technology, Kevin Street, Dublin 8, Ireland,  haq.nawaz@dit.ie 
Received (in XXX, XXX) Xth XXXXXXXXX 200X, Accepted Xth XXXXXXXXX 200X 
First published on the web Xth XXXXXXXXX 200X 15 
DOI: 10.1039/b000000x 
Abstract 
 
Confocal Raman Micro spectroscopy (CRM) is employed to examine the chemical and physiological effects of anticancer agents, using 
cisplatin and A549 adenocarcinoma cells as a model compound and test system respectively. Spectral responses of the membrane and 20 
cytoplasm of the cell are analysed independently and the results are compared to previously reported spectroscopic studies of the nucleus. 
Moreover, Raman spectra from the proteins extracted from the control and exposed samples are acquired and analysed to confirm the 
origin of the molecular changes of the cell membrane and cytoplasm of the A549 cells. Multivariate data analysis techniques including 
Principal Component Analysis (PCA) and Partial Least Square Regression (PLSR) along with PLS-Jack knifing are used to analyse the 
data measured from the cell membrane and cytoplasm of the A549 cells and results are correlated with parallel measurements from the 25 
cytotoxicity assay MTT. A PLSR model is used to differentiate between the chemical effect of the chemotherapeutic agent and the 
physiological response of the A549 cells and to identify regions of the spectrum that are associated with these processes respectively. The 
PLSR model is also employed to predict, on the basis of the Raman spectra, the effective dose as well as the level of physiological 
response, using spectra data from the cytoplasmic and cell membrane regions. The effectiveness of the models based on spectral datasets 
from the cell membrane and cytoplasm is compared to similar models constructed using spectral data from the nuclear region as well as 30 
one combining spectral data from all regions. In all cases, higher prediction accuracy is found for regression against the cisplatin dose, 
and for both regression against dose and physiological response, nuclear data yields higher precision. 
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Introduction 
 
The study of the interaction of anticancer agents with 
cancer cell model systems is considered to be very 
important at the preclinical stage of the drug development 5 
process in order to establish the mechanism of action of the 
drug as well as the response of the cell to the 
chemotherapeutic agent. There is great need for the 
development and establishment of a non-invasive 
analytical technique which not only can be used for the 10 
analysis of the binding mechanism of the anticancer agents 
to their targets but which can also analyse the biological 
processes of the cell which occur in response to the action 
of the drug and ultimately predict the drug efficacy. 
Confocal Raman Micro spectroscopy (CRM) has emerged 15 
as a viable analytical tool for the analysis of biological 
tissue 1 and the effect of external agents on the cell 1-5. The 
technique is being explored extensively for the analysis of 
biological systems because it is non-invasive, cost 
effective, rapid, requires no sample labelling prior to 20 
analysis and gives high content information 6. It is capable 
of investigating sub-cellular biochemical structures 7, 8 and 
has already been explored for  the analysis of the 
interaction of a range of chemotherapeutic agents with 
biological macromolecules 9 and with cancer cells 6, 10-12.  25 
In order to validate the technique of CRM for quantitative 
measurement of the biochemical and physiological effects 
of novel chemical treatments, it is necessary to 
demonstrate and evaluate the technique for anticancer 
agents whose mechanism and efficacy of action is well 30 
known. The use of CRM for the analysis and prediction of 
the chemotherapeutic response of A549 cells to the action 
of the cisplatin (cis-Diamminedichloroplatinum (II)), based 
on analysis of the nuclear signals, has recently been 
demonstrated 13. The use of both cisplatin dose, as well 35 
cellular response as defined by the cytotoxicity assay, 
MTT, as targets for PLS regression enabled a 
differentiation between the spectral changes associated 
with the direct chemical interaction with the nucleus and 
the resultant metabolic response. 40 
It is also of great importance to understand and 
characterize the biochemical changes in the membrane and 
cytoplasm of cells during the course of the action of 
chemotherapeutic agents. These can occur due to the 
primary interactions during uptake of the agent, but also as 45 
a result of the subsequent cellular response. Cisplatin is 
widely used to treat a variety of cancers including lung, 
ovarian, colon, cervical, bladder, head and neck and 
testicular cancers, either as an individual agent or in 
combination with other drugs14-17. Its mechanism of 50 
chemical interaction is well characterised. While entering 
the cell, cisplatin interacts with lipids of the cell membrane 
which may affect the function of the cell membrane 18, 
while inside the cytoplasm, it may bind to RNA and thiol 
groups of peptides and proteins 19. In the cytosol, binding 55 
of cisplatin with some proteins may lead to the 
development of cytoxicity and resistance 20. In the nucleus, 
it binds with DNA forming inter-strand and intra-strand 
crosslinks which lead to cell cycle arrest and apoptosis, the 
primary cytotoxicological response 21. 60 
In the current study, the capabilities of CRM for the 
elucidation of the mechanism and efficacy of 
chemotherapeutic agents are further evaluated by exploring 
the spectral changes in the cell membrane and cytoplasm, 
using cisplatin and A549 adenocarcinoma cells as a model 65 
compound and test system respectively. Spectra of the cell 
membrane and cytoplasm of A549 cells were taken after a 
96 hour exposure period to the agent, and multivariate 
models of the variation in spectral content with levels of 
exposure and degrees of cytotoxicological response, as 70 
determined by the MTT assay were constructed. A feature 
selection technique was then used to identify regions of the 
spectrum that were associated with the biochemical effect 
of exposure to the agent, and with the subsequent 
cytotoxicological response of the cells. Finally, 75 
multivariate Partial Least Squares Regression is used to 
demonstrate the capabilities of Raman spectral analysis to 
predict both the exposure dose and viability of the cell 
culture and results are compared to those previously 
reported for spectroscopic analysis of the nuclear regions 80 
only13. 
 
Materials and methods 
 
Cell culture 85 
 
A549 human lung adenocarcinoma cells were obtained 
from ATCC (CCL-185). The cells were cultured in DMEM 
F-12 (Sigma Aldrich, Ireland) medium supplemented with 
10% FBS, 1µg/ml hydrocortisone (Sigma), 2mM L-90 
glutamine (Gibco) and 1% penicillin- streptomycin 
(Gibco). Cells were incubated at 37°C
 
in 5% CO2 and 
routinely subcultured with a 1:1 ratio of 0.25% trypsin and 
0.1% EDTA when they reached 70-80% confluency. 
 
 95 
Cell exposure and cytotoxicity assay 
 
Cisplatin, obtained from Sigma Aldrich, Ireland, was 
dissolved in 1% NaCl (Sigma Aldrich, Ireland) solution 
(pH 7) to prepare the stock solution. Working solutions of 100 
the drug were prepared in cell culture media. A 96-hour 
period of exposure to cisplatin was chosen along with a 
wide range of exposure concentrations ranging from 0.05-
50 µM, as this covers the range of the cytotoxic response 
and provided a dataset upon which to base a regression 105 
model to demonstrate the predictive ability of the Raman 
spectral measurements. Cytotoxicity was measured 
according to the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] assay, obtained from Sigma 
Aldrich, Ireland. MTT is a molecular assay whose colour is 110 
changed by mitochondrial reductases in living cells, and it 
is therefore commonly used as an indicator of cell viability 
and proliferative capacity and thus the cytotoxicity of 
chemical agents. 
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The MTT assay was performed in triplicate according to a 
method reported previously 22 with a slight modification 13.  
Cells were cultured in 96-well plates (Nunc, Denmark) at a 
density of 2 × 103 cells per well in DMEM-F12 medium 5 
with all the supplements as listed above. After 24 hrs of 
initial cell attachment, the plates were washed with 100 
µl/well phosphate buffered saline (PBS) and were treated 
with varying concentrations of cisplatin in the range from 
0.05 µM- 50µM (including a separate unexposed control 10 
sample). Following a 96-hour exposure period, the cells 
were rinsed with PBS and 100 µl of fresh medium (without 
supplements) were added to each well. A volume of 10 µl 
of MTT (5mg/ml) prepared in PBS was then added to each 
well and the plates were incubated for 3 hrs at 37 °C in a 15 
5% CO2 humidified incubator. After this incubation period, 
the medium was discarded, the cells were washed with 100 
µl of PBS and 100 µl of DMSO was added to each well to 
extract the dye. The plates were then shaken 240 times per 
minute for 10 min and the absorbance was measured at 570 20 
nm using a micro plate reader (Tecan Genios, Grodig, 
Austria). Six replicate wells were used for each exposure.  
 
Protein extraction 
 25 
The cellular protein was extracted from both a control 
sample of A549 cells together with a sample of A549 cells 
exposed to 3 µM cisplatin for 96 hours. The 3 µM 
exposure level was chosen as it provided the means to 
examine the ability of CRM to identify relatively small 30 
levels of changes in protein, structural and conformational, 
as a result of cisplatin binding. As determined using the 
cytotoxicity assay, at this concentration, the viability has 
reduced to approximately 30% and thus it represents the 
inverse exponential point of the response. Briefly, cells 35 
were trypsinised and centrifuged to form a pellet of cells, 
and 1 ml TRIzol reagent (Invitrogen) per 5 - 10 × 106 cells 
was added. The samples were then homogenized and 
incubated at room temperature for 5 min to induce cell 
lysis. For each ml of TRIzol reagent, 200 µl of chloroform 40 
was added and samples were centrifuged at 12,000 × g for 
5 min at 4 °C. Following centrifugation, the mixture 
separated out into a lower red organic phase, a thin 
interphase and a colourless upper aqueous phase. Then 300 
µl of 100% ethanol per ml of TRIzol reagent was added to 45 
the interphase and organic phase followed by mixing and 
spinning which yielded a pellet and supernatant. The 
supernatant was used to extract the proteins. To precipitate 
proteins, 1.5ml of isopropanol/ml of Trizol reagent used 
was added for initial homogenization. The samples were 50 
stored at room temperature for 10 minutes and sedimented 
by centrifugation at 12000xg for 10 min. and 4 °C. The 
supernatant was removed and the protein pellet was 
washed three times with 0.2M guanidine thiocyanate to 
remove phenol and dye. After the final wash, the protein 55 
pellet was vortexed in 2 ml 100% ethanol and was stored 
in ethanol for 20 minutes at room temperature. After that, 
the pellet was air dried and dissolved in 1% SDS (Sodium 
Dodecyl Sulphate) and then incubated at 50 °C, to extract 
the proteins from the pellet. The insoluble material was 60 
sedimented by centrifugation at 10,000 g for 10 min. at 4 
°C and the supernatant containing total cellular proteins 
was transferred into a clean tube. To get the proteins in 
pellet form from this supernatant, acetone precipitation of 
the proteins was performed. To do this, equal volumes of 65 
the ice-cold acetone was added to the protein supernatant 
and incubated on ice for 15 minutes followed by the 
centrifugation for 10 min. at 12000 x g in a pre-cooled 
microcentrifuge at 4 ë. The supernatant was discarded and 
pellet was air dried. In order to verify the purity of the 70 
proteins, the absorbance of the sample was recorded on a 
UV-Vis spectrophotometer at 260nm and 280nm. A ratio 
of 0.6 (A260/A280) is characteristic of pure protein. The 
pellet was dissolved in dH2O, as water has a significantly 
weaker Raman signal than common organic solvents, and 75 
was used immediately for analysis by Raman 
spectroscopy. 
 
Sample preparation for Confocal Raman Spectroscopy 
 80 
For CRM, cell samples were cultured on quartz substrates 
according to a protocol outlined elsewhere 1. Briefly, 
quartz coverslips were coated with a 2% w/v gelatin-water 
solution and maintained at 4 °C for 6 hrs to allow 
polymerization of the gelatin to the substrate. 85 
Subsequently, 2.5 × 103 A549 cells were attached to the 
substrates for a 48 hour period, and were exposed to the 
cisplatin concentrations in the range 0.05 µM- 50µM for a 
96-hour period (together with a non-exposed control 
sample). After the exposure period, the cells were fixed in 90 
4% formalin for 10 minutes and were stored in 0.9 % 
physiological saline solution at 4 °C until the Raman 
analysis was performed 5. Fixing the cells allows 
prolonged periods of storage and measurement. In a 
previous study, it has been demonstrated that although all 95 
commonly employed fixatives result in some degree of 
nucleic acid degradation, protein denaturation, and lipid 
leaching, fixing in formalin, in comparison to other 
fixatives, best preserves the integrity of the cells compared 
to live cells.5 All samples were prepared in triplicate. 100 
 
Spectral Acquisition  
 
CRM was conducted with a Horiba Jobin-Yvon, LabRam 
HR800 instrument using a 785 nm laser as source. The 105 
laser power was approximately 70 mW at the sample. 
Spectra were taken in the range from 600 cm-1 to 1800 cm-
1
 with a confocal hole diameter of 100µm. A ×100 water 
immersion objective was used to focus the laser on the 
sample, immersed in 0.9% saline. The spatial resolution of 110 
the instrument has previously been checked by performing 
a linescan of 1µm Iron oxide particles with a 0.2 µm step 
size, which produced a profile of 1.5µm FWHM, implying 
a spotsize of 1.12µm7.Multiple spectra were recorded from 
the cell membrane and cytoplasm portion and nucleus for a 115 
previously reported study13 of a total of 60 cells at each 
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cisplatin exposure level, by performing a line scan across 
each cell as illustrated in Figure 1(a). Each scan was set 
up by initially focussing on the nucleus of the cell. 
Subsequently, the spectra were filtered with a Savitsky-
Golay filter (order 5, 13 point window), and the quartz 5 
signal background was subtracted using algorithms 
developed in-house. Prior to analysis, the spectra were also 
vector normalized. For the acquisition of the spectra from 
the extracted protein, the protein dissolved in water was 
drop cast onto quartz substrates immediately prior to 10 
measurement.  
 
Data analysis 
All spectral analysis was performed in the Matlab 7.2 (The 
Mathworks Inc.) environment employing the PLS Toolbox 15 
5.0.3 (Eigenvector Research, Wenatchee, WA) and 
algorithms developed in-house. Outlying spectra were 
removed using Grubb’s filtering 23. All spectra, including 
calibration and substrate backgrounds, were vector 
normalized. The substrate spectra were subtracted from 20 
each spectrum and a fifth order polynomial was fitted to 
and subtracted from the spectra to remove any residual 
spectral baseline. Multivariate regression models were 
constructed using Partial Least Squares Regression (PLSR) 
24
 and PLS Jack-knifing was employed as a multivariate 25 
feature selection technique 25-27. The PLSR algorithm seeks 
to develop a model that relates the spectral data (X-matrix) 
to a series of targets (Y-matrix, e.g. concentration of 
reaction product or analyte) according to the equation 
Y=XB+E, where B is a matrix of regression coefficients 30 
and E is the regression residual. The Y-matrix here 
consisted of values of the concentration of cisplatin to 
which the cell was exposed, or the measured level of cell 
viability from the MTT assay. The PLS Jack-knifing 
method developed by Martens and colleagues was then 35 
used to determine the spectral features that were 
statistically significant at a particular level of confidence 
using t-testing of the regression coefficients, B. 27. The 
Raman band assignments used in interpretation of the 
spectral features were taken from the literature 28-32. 40 
 
Results and Discussion 
 
Comparison of the mean control spectra of the cell 
membrane, cytoplasm and nucleus 45 
 
The mean control spectra of the cell membrane, cytoplasm 
and nucleus of A549 cells are shown in Figure 1(b). The 
mean control spectra of all the three cellular components 
appear similar to the naked eye. In a similar analysis of 50 
live cells using K-means clustering, the nuclei, cytoplasm 
and membrane were clearly differentiated and spatially 
located, but the average K-cluster spectra showed similarly 
few identifiable spectral differences7. This is perhaps not 
surprising as, with a 1µm spot size, the nucleus can be 55 
specifically targeted, but the overlying cellular membrane 
and cytoplasm will also contribute to the spectrum 
acquired. Similarly, the spectrum of the cytoplasm will 
contain contributions from the overlying cellular 
membrane and potentially also from subcellular organelles 60 
such as mitochondria, lysosomes, etc., and inevitably the 
spectra of the cell membrance will contain contributions 
from the neighbouring cytoplasm.   
Careful analysis of the spectra reveals however some 
differences which distinguish the spectra of the cell 65 
membrane and cytoplasm from the nucleus as 
demonstrated by the scatter plot of the Principal 
Component Analysis (PCA) shown in Figure 2(a). There 
is very good separation indicating that the spectra for the 
three cellular components are different and these 70 
experimental settings can be used for acquiring reliable 
spectra from the samples. The cellular regions are 
effectively separated according to PC1 which accounts for 
95.58% of the variance and the spectral loadings are 
illustrated in Figure 2(b). The Raman bands which 75 
differentiate the mean control spectra of the three cellular 
components are indicated by arrows (and by solid lines in 
Figure 1(b)) and these are also bands in which changes 
due to the action of the cisplatin are expected. The band at 
726 cm-1, which can be assigned to tryptophan and/or CH3 80 
stretching of the lipids, is present in the cytoplasm and cell 
membrane spectra but is not prominent in the nuclear 
spectra. The Raman band at 1423 cm-1 is assigned to CH3 
deformation of aromatic lipids and is present in the spectra 
of the cell membrane and cytoplasm but is similarly not 85 
prominent in the spectra of the nucleus. Another band at 
1510 cm-1, assigned to C=C stretching of proteins 
(Tryptophan, Tyrosine amino acids), is present in the mean 
spectra of the membrane and cytoplasm but absent in the 
nuclear mean spectra. The two Raman bands which are 90 
present in all three mean spectra, indicated by dotted lines, 
correspond to C-H deformation of lipids/proteins (1449 
cm-1) and the amide-I band for proteins (1660 cm-1). Due 
to the action of the cisplatin, changes in these bands are 
also expected. 95 
For the nuclear mean spectra, the important Raman peaks 
which are different from the spectra of the cytoplasm and 
cell membrane are labelled. The Raman band at 718 cm-1 
can be assigned to adenine while the bands at 807 cm-1 and 
827 cm-1 are assigned solely to O-P-O stretching of the 100 
DNA-A and B-form respectively and that at 1065 cm-1 
assigned to the O-P-O stretching of the DNA backbone in 
general. These three Raman markers of the DNA backbone 
are present in the spectra of the nucleus with much higher 
intensity as compared to the spectra of the cytoplasm and 105 
membrane. The Raman bands at 669 cm-1 (Thymine) and 
1336 cm-1 (Guanine) are present, both in the mean spectra 
of the nucleus and cytoplasm which is expected, as their 
presence in the cytoplasm may be due to cytoplasmic 
DNA, and are unexpectedly seen in the membrane spectra 110 
which may be the contribution from the surrounding 
cytoplasm 29. 
Comparing the mean control spectra of the nucleus of 
A549 cells with that of the cell membrane and cytoplasm, 
ideally, there should be no peaks in the nuclear spectra for 115 
the lipids (CH deformation, 1449 cm-1) but their presence 
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Figure 1 b: Mean control spectra of the (nucleus, cytoplasm and cell membrane) of A549 cells, the spectra are normalized and off set for 
clarity and shading shows the error bars. 
 
Figure 1 a: Image of an A549 cell (control) showing the range of a 
typical line map, as well as the points at which Raman spectra were 
recorded. 
may be due to the contribution from the surrounding 
cytoplasm 33 and 29 or on the other hand this band can be 
assigned, both to lipids and proteins 34. 
 
Cytotoxicity of cisplatin 5 
 
The dose response curve representing the cytotoxic 
response of cisplatin to A549 cells after 96 hrs is presented 
in Figure 3 (reproduced from results published 
elsewhere)13, where the level of viability in each sample 10 
was normalised to that in the control sample. Due to the 
action of the drug, the mitochondrial activity decreases 
monotonically which in turn leads to a decrease in cell 
viability. The Inhibitory Concentration (IC50) value was 
derived from the data by a fit of f(x) = min + (max-15 
min)/(1+(x/IC50)^n) and found to be 1.2 ± 0.2µM, which is 
consistent with the literature. For A549 cells exposed to 
test drug concentration (TDC) for 72 hrs, IC50  values of 
3.59µM and 2.2 µM are reported elsewhere with MTT and 
ATP assays respectively 35. Also, Cordes et al. have 20 
determined an IC50 value of 2.0 µM for cisplatin (0.1-50 
µM) exposed A549 cells using the colony formation assay 
36
. 
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Figure 2 a: Scatter plot of the Principal Component Analysis of the spectra of the nucleus, cytoplasm and cell membrane of control A549 cells 
Figure 2 b: Loadings of PC1 from the Principal Component Analysis of the Raman spectra taken from the nucleus, cytoplasm and cell membrane of the control A549 cells. 
 
 
 
 
 
 
 35 
 
 
 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  7 
Figure 3: A549 cell viability (measured by MTT absorbance) at 96 hours after exposure to Cisplatin. Error bars denote the standard error on the 
mean at each concentration. 
 
 
Effect of cisplatin exposure on the spectra of cell membrane 
 
Figure 4 shows the mean control (A) and difference 30 
spectrum of the cell membrane (B) of A549 cells exposed 
to 3 µM cisplatin versus its control. It should be noted that 
no significant contributions due to the cisplatin itself are 
expected, as its Raman spectrum is dominated by bands in 
the region between 100-550 cm-1 (Nawaz et al., 2010), 35 
which does not fall within the 600-1800 cm-1 spectral 
window of the current measurements. The most prominent 
changes are observed in the bands related to proteins at 
671 cm-1 and 728 cm-1 (ring breathing of the tryptophan), 
1030cm-1 (C-H bending), 1094 cm-1and 1126 cm-1 (C-N 40 
stretching) and 1655 cm-1 (amide-I). In addition to this, 
shifts in some of the Raman bands are also observed, 
including 1094 to 1097 cm-1 and 1126 to 1129 cm-1 (C-N 
stretching) and 1655-1659 cm-1 (amide-I) as labelled in the 
mean difference spectra.    45 
The Raman bands at 1371 cm-1 (CH3 stretching) and 1448 
cm-1 (CH deformation), related to cell membrane lipids, 
also undergo shifts from 1371 to 1376 cm-1 and 1448 to 
1450 cm-1. These spectral changes and shifts in the Raman 
signatures of the membrane proteins and lipids are 50 
consistent with the well known direct interaction of 
cisplatin 37 and may also provide indications of the indirect 
action of the agent on cellular function 18. 
 
Mean control and difference spectra of the cytoplasm 55 
 
 
 
The mean control and difference spectra of the cytoplasm 85 
of A549 cells exposed to 3 µM cisplatin are shown in 
Figure 5 A and B respectively. The bands in which the 
major changes are observed are related to proteins, and 
include 671 cm-1, 728 cm-1, 1210 cm-1 (Tryptophan ring 
breathing), 939 cm-1, (C-C skeletal stretching, ά-helix), 90 
1129 cm-1 (C-N stretching), 1179 cm-1 (C-H bending, 
Tyrosine), 1260 cm-1 (amide-III, β-sheets) and 1658 cm-1  
(amide-I) along with shifts in some bands like 671 to 674 
cm-1, 728 to 731 cm-1, (Tryptophan ring breathing), 1260 to 
1265 cm-1 (amide-III, β-sheets) and 1658 to 1661 cm-1 95 
(amide-I) as labelled in the mean difference spectra. These 
changes can be important Raman signatures of the binding 
of the cisplatin with the proteins in the cytoplasm of the 
cell 19 which may lead to the development of cytoxicity 
and resistance 20 and cause changes in their secondary and 100 
tertiary structures. 
 
Spectra of extracted protein 
 
In order to further confirm the Raman markers for the 105 
direct chemical action of cisplatin and the cytotoxic 
response of the A549 cells to the cisplatin exposure from 
the cell membrane and cytoplasm, the spectra recorded of 
the protein extracted from the control and exposed (3 µM 
for comparison to the spectroscopic analyses of the cells) 110 
A549 cells were analyzed. The mean control and the 
difference spectra of the extracted protein are shown in  
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Figure 4: Mean spectrum of the cell membrane of control sample (A) and the difference spectrum (B) between the mean of the control and the sample exposed to 3µM 
cisplatin. The shaded area around each trace defines the standard error on the mean. 
 
Figure 5: Mean spectrum of the cytoplasm of control sample (top) and the difference spectrum (bottom) between the mean of the control and the sample exposed to 3µM 
cisplatin. The shaded area around each trace defines the standard error on the mean. 
 
 
 65 
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Figure 6. The major changes observed in the Raman bands 
include an increase in the intensities of the C-C skeletal 
stretching (904 cm-1, 935 cm-1), phenyl alanine (1001 cm-
1), C-N stretching (1061 cm-1, 1131 cm-1), Tyrosine ring 
breathing (639 cm-1, 961 cm-1, 1199 cm-1), Tryptophan ring 5 
breathing (1011 cm-1), CH deformation (1323 cm-1 and 
1404 cm-1 ) and C=C bending (1606 cm-1). 
It should be noted that the extract does not differentiate 
between membrane and cytoplasmic proteins and that the 
in situ cellular environment is very different from that of 10 
the ex situ dried state, and thus that the spectral changes of 
figure 6 cannot be quantitatively compared to those 
observed in the cells. Nevertheless, the spectral changes in 
the protein extracted from cisplatin exposed compared to 
control cell cultures confirms a significant modification of 15 
the protein structure as a result of the exposure, by direct 
or indirect means. Normally, in a cell, proteins are folded 
in a well-ordered structure and the side chains of the 
proteins are constrained 34 and thus the intensities of these 
Raman bands are suppressed in the spectrum of the control 20 
as compared to the exposed. The increase in the intensities 
of these bands may be due to the direct binding of the 
cisplatin to the associated proteins which causes changes in 
their secondary structure and causes their unfolding, 
exposing the phenylalanine/tyrosine/tryptophan side 25 
chains. These changes can be taken as the Raman 
signatures of the known action of the cisplatin binding to 
proteins in the cell membrane and cytoplasm 19 of A549 
cells. Moreover, changes in the amide-I band (1660 cm-1) 
along with a shift (1660 to 1665 cm-1) and amide-III, β-30 
sheet (1252 cm-1) along with a shift (1252 to 1257 cm-1), 
are also observed. These two Raman bands are frequently 
used to allocate secondary structure to the proteins 38 and 
the shifts observed in these bands can be the Raman 
markers of the conformational changes in the associated 35 
proteins as a result of the action of the cisplatin. 
The changes observed in the Raman spectra of the 
extracted proteins can also be identified in the mean 
control and difference spectra of the cell membrane or 
cytoplasm or both albeit with slight deviations of their 40 
positions. Notably prominent in both are the bands related 
to C-C skeletal stretching (904 cm-1, 935 cm-1), C-N 
stretching (1131cm-1), Tyrosine ring breathing (1199 cm-1), 
CH deformation of the proteins (1449 cm-1) , amide-I band 
(1660 cm-1) and amide-III, β-sheet (1252 cm-1). These 45 
results confirm those obtained from the data of cell 
membrane and cytoplasm. 
 
Feature Selection by PLS Jack-knifing for the data of the Cell 
membrane 50 
 
For a fixed exposure concentration, the analysis of the 
mean difference spectra for cytoplasm and cellular 
membrane highlight the effects of the cellular interaction 
with the cellular structures which can be the result of the 55 
direct chemical interaction of the agent or the resulting 
physiological (cytotoxic response). The former should be 
correlated with the applied dose, whereas the latter should 
be correlated with the physiological response (Figure 3). 
In an attempt to differentiate the responses, the spectral 60 
data, for each cellular region, over the whole exposure 
range, were subjected to a multivariate Partial Least 
Squares Regression (PLSR), using the chemical 
concentration and cytotoxicological response, respectively. 
The PLS Jack-knifing procedure was furthermore 65 
employed to identify the spectral features of maximum 
variance as a function of the respective parameters. 
The regression co-efficients obtained by PLS-Jack knifing 
for the cell membrane data, regressed against cisplatin 
concentration (Figure 7 A), give useful information  70 
regarding the signatures of the cisplatin attack on the cell 
membrane while entering the cell (chemical effect). As a 
result of interaction with the cisplatin, significant changes 
in the bands related to lipids at for example 1420-1426 cm-
1
, 1436-1440 cm-1,  (CH3 deformation) and 1447-1466 cm-1 75 
, 1474-1483 cm-1(CH deformation) are observed, which 
may be indicative of the interaction of the cisplatin with 
the membrane lipids. Also, a positive shift of the band at  
1449 cm-1, (C-H deformation) to 1466 cm-1 is observed in 
the mean difference spectra, (Figure 3 B), On the basis of 80 
the information derived, it seems that cisplatin interacts 
with the membrane lipids and causes some changes in their 
structure. It has been reported by 37 that cisplatin interacts 
with the membrane lipids which can cause neurotoxicity 
and that this interaction with the lipid bilayer can cause an 85 
increase in the isotropic/hexagonal lipid phases at the cost 
of the lamellar phase. 
Further changes at 713-717 cm-1, 833-842 cm-1, 1556-1563 
cm-1 associated with tryptophan ring breathing along with 
the changes in the bands at 622-627 cm-1, 852-860 cm-1, 90 
1135-1147 cm-1 assigned to C-C stretching vibrations and 
1122-1129 cm-1, 1161-1163 cm-1 assigned to C-N 
stretching vibrations, 1485-1495 cm-1 (C-H deformation of 
proteins) are related to the proteins. Additionally, changes 
in the bands at (1242-1244, 1246-1255) assigned to amide-95 
III β-sheets and at (1270-1316) of amide-III ά-helix and 
(1649-1652, 1659-1685) assigned to amide-I ά-helix are  
also observed. These changes can be attributed to the 
structural changes occurring in the proteins of the cell 
membrane due to the attack of the drug, as also discussed 100 
in the information observed in the mean difference spectra 
of the cell membrane.   
The regression co-efficients obtained by PLS-Jack knifing 
for the cell membrane data, regressed against cell viability 
(physiological effect), are shown in Figure 7 B. The bands 105 
of ring breathing of tryptophan (711-736 cm-1, 748-753 
cm-1, 758-774 cm-1), out plane ring breathing of tyrosine 
(826-830 cm-1), and C-C skeletal vibrations (883-898 cm1, 
903-923, 928-931, 934-935) along with C-N stretching 
(1111-1116 cm-1, 1120-1129 cm-1) and CH2 rocking (740-110 
744 cm-1) are related to proteins which can be attributed to 
the changes in the secondary and tertiary structures of the 
proteins due to the changes in the physiology of the cell 
and others in the stretching vibrations of the C-C head 
group of the lipids (939-980 cm-1), CH deformation of the  115 
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Figure 6: Raman spectra of protein extracted from A549 cells; Mean of the control and exposed to 3 µM cisplatin for 96 hrs (A), the zoomed in region, 1199-1800, (A-1), 
difference spectra (B) and the zoomed in region, 1199-1800, (B-1). The shaded area defines the standard error on the mean. 
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Figure 7: PLS-Jack knifing analysis, A (regressed against cisplatin concentrations) and B (regressed against cell viability) of the cell membrane spectra of  A549 cells 
exposed to 0.05µM-50µM cisplatin for 96 hrs. 
 
 
lipids (1424-1439 cm-1, 1445-1455 cm-1), provide the 40 
Raman signatures of the  structural changes in the 
membrane lipids as a result of the changes in the 
physiology (cell viability) of the cell. 
Comparing the regression co-efficients obtained via 
spectral regression against cisplatin concentrations (which 45 
highlight the primary chemical effect of the action of the 
agent) with those obtained via regression against cell 
viability (which highlight biochemical markers of the 
change in the viability of the cell), very different spectral 
features are selected as being statistically significant and 50 
thus allow the differentiation of the chemotherapeutic 
response.  
The spectral features which are changed only due to the 
chemical effect and not due to the physiological effect are 
bands related to lipids 1270-1316 cm-1 (CH2 twist), 1420-55 
1426 cm-1, 1436-1440 cm-1, 1447-1466 cm-1 (C-H 
deformation) and bands related to proteins including 1485- 
1495 cm-1 (C-H deformation of proteins), (713-717 cm-1, 
833-842 cm-1, 1556-1563 cm-1) of tryptophan ring  
 
breathing among others. This may indicate that the 
chemical interaction of the cisplatin with the membrane 
proteins and lipids results in disintegration of the lipids and 100 
changes in the conformation of the membrane proteins.   
On the other hand, the spectral features which are changed 
only due to the physiological effect and not due to the 
chemical effect are related mainly to the proteins of the 
cell membrane 877-881 cm-1 (Glutamine residues), 883- 105 
898 cm-1, 903-923 cm-1, 928-931 cm-1, (C-C skeletal 
stretching), 958-987 cm-1 (C-C skeletal β-sheets) which 
may be due to the membrane protein signalling as a result 
of the attack and action of the cisplatin on the cell 
membrane. 110 
 
Feature Selection by PLS Jack-knifing for the data from 
Cytoplasm 
 
For the cytoplasm data, the regression co-efficients 115 
obtained by PLS-Jack knifing, are shown, for regression 
against cisplatin concentrations (Figure 8 A) and against 
cell viability (Figure 8 B).  
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As a result of the chemical effect (Figure 8 A), features 
primarily related to proteins are identified. In addition to 
the observations of the same Raman bands for proteins as 
observed in the mean difference spectra (Figure 4 B), Jack 5 
knifing results for cytoplasm data show that there is a 
positive shift of the amide I band from 1664 cm-1 to 1676 
cm-1 with increasing cisplatin concentration, which may be 
indicative of the changes in the secondary and tertiary 
structure of the protein. 10 
The regression against the cell viability (Figure 8 B) 
shows features related to the change in the cell physiology 
due to the action of the cisplatin and include tryptophan 
ring breathing (714-715 cm-1, 724-727 cm-1, 764 cm-1), CH 
bending (1390-1393) and also, ribose ring breathing of the 15 
RNA (1057 cm-1) and many others which are highlighted. 
The changes which are seen only due to the chemical 
effect and not due to the physiological effect include bands 
assigned to out of plane ring breathing of tyrosine (824 cm-
1), related to C-C stretching vibrations (862 cm-1), C-N 20 
stretching (1073-1074 cm-1), C-C stretching related to 
skeletal changes of proteins. 
On the other hand, the changes which are seen only due to 
the physiological effect and not due to the chemical effect 
are related to tryptophan ring breathing (714-715 cm-1, 25 
724-727 cm-1, 764 cm-1), CH bending (1390-1393 cm-1) 
and also, ribose ring breathing of the RNA (1057 cm-1). 
 
PLS-model for the prediction of levels of the exposures and 
cellular viability  30 
 
CRM can clearly fingerprint the effects of the interaction 
of the chemotherapeutic agent within the cellular regions 
and identify that fingerprint within the cellular spectra of 
exposed cells. PLSR models of A549 cellular membrane 35 
and cytoplasmic spectra versus concentration and viability 
measurements from the MTT assay were constructed to 
determine the ability of the Raman spectral data to predict 
the level of exposure to cisplatin and the resultant 
physiological effect. 40 
For the construction of the PLSR model, all spectra of each 
cellular region were compiled into a matrix, and were 
randomly sorted. A total of 60% of the spectra were used 
to train the PLSR regression model and 40% of the total 
was retained as an independent test set to assess the 45 
performance of the model in predicting the level of 
exposure, and the cellular viability, with unseen data. 
Leave-one out cross validation with the calibration set was 
used to determine the optimal model complexity for use in 
testing 26. This process was performed on fifty separate 50 
occasions, with randomization of the data matrix and 
splitting of the data on each occasion to prevent data bias 
24
. The reliability/uncertainty of the model can be 
determined from the results from the values of the root 
mean square error of calibration (RMSEC) and the root 55 
mean square error of prediction (RMSEP). Control of 
overfitting was achieved using a procedure previously 
described by Martens and Naes39. The procedure involves 
selection of the optimal number of latent variables to retain 
within the PLS model via ten-fold cross-validation with the 60 
calibration data set. The optimal number of LV's was then 
selected on the basis of the number which provided the 
lowest root mean squared error at cross validation. 
An example of the results of the PLSR model prediction of 
the cellular viability for the cell membrane data is shown 65 
in Figure 9, where the values of the root mean square error 
of calibration (RMSEC) and the root mean square error of 
prediction (RMSEP) denote the prediction uncertainty. The 
mean values of the RMSEC and RMSEP for the PLSR for 
prediction of the level of exposure to cisplatin (from the 70 
spectra of cell membrane) were found to be 3.01 µM and 
4.74 µM respectively. The associated values of RMSEC 
and RMSEP for PLSR against normalized cellular viability 
were 0.06 and 0.12 respectively. The RMSEP for 
prediction of cisplatin concentration is therefore 9.48% 75 
over the full scale range (0 to 50 µM), and 12% over the 
full scale range of viability (from 0 to 1).  
The mean values of the RMSEC and RMSEP for the PLSR 
for prediction of the level of exposure to cisplatin (from 
the spectra of cytoplasm) were found to be 1.47 µM and 80 
3.74 µM respectively. The associated values of RMSEC 
and RMSEP for PLSR against normalized cellular viability 
were 0.07 and 0.14 respectively. The RMSEP for 
prediction of cisplatin concentration is therefore 7.48% 
over the full scale range (0 to 50 µM), and 14% over the 85 
full scale range of viability (from 0 to 1). 
In the previous study of the nuclear spectra of the same 
system, the mean values of the RMSEC and RMSEP for 
the PLSR for prediction of the level of exposure to 
cisplatin were found to be 1.67 µM and 3.41 µM 90 
respectively. The associated values of RMSEC and 
RMSEP for PLSR against normalized cellular viability 
were 0.05 and 0.11 respectively. The RMSEP for 
prediction of cisplatin concentration is therefore 6.8% over 
the full scale range (0 to 50 µM), and 11% over the full 95 
scale range of viability (from 0 to 1). 
Furthermore, the spectral data from cell membrane, 
cytoplasm and nucleus was combined and a PLSR model 
was constructed to predict the level of exposure and 
cellular viability on the basis of the combined spectral 100 
changes. The values of the RMSEC and RMSEP for PLSR 
for prediction of level of exposure were found to be 6.44 
and 8.15 µM and against the normalised cellular viability 
0.148 and 0.186 respectively. The RMSEP for prediction 
of cisplatin concentration is therefore 16.3 % over the full 105 
scale range (0 to 50 µM), and 18.6 % over the full scale 
range of viability (from 0 to 1). 
Table 1 summarises the prediction accuracies of the PLSR 
models based on the individual cellular components as 
well as the combined data, for regression against both the 110 
cisplatin dose and the cell viability. Figures in brackets 
denote standard deviations. In all cases, higher prediction  
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Figure 8: PLS-Jack knifing analysis, A (regressed against cisplatin concentrations) and B (regressed against cell viability) of the cytoplasm spectra of A549 cells exposed to 
0.05µM-50µM cisplatin for 96 hrs. 
 
accuracy is found for regression against the cisplatin dose, 
and for both regression against dose and physiological 
response, nuclear data yields higher precision.  
As cisplatin primarily interacts with DNA in the nucleus, 5 
the largest effects of the agent are manifest there, either 
due to the direct chemical interaction of the drug or due to 
the physiological response of the cell to it. This may be the 
reason why the PLSR model gives the highest prediction 
accuracies for both the level of exposure and cell viability, 10 
for the nuclear data. 
It should further be noted that PLSR is a linear model, and 
is thus limited for a nonlinear response. In operational 
models of pharmacological agonism, the relationship 
between the agonist concentration and that of receptors 15 
occupied by the agonist is in itself a hyperbolic function 40 
and thus it may be expected that the direct chemical effect 
as a result of the interaction of cisplatin with nuclear DNA  
 
or other subcellular molecular components, as monitored 20 
by Raman spectroscopy is not a linear function. The 
dependence of the physiological effects on the agonist 
concentration is a further complex function, as a result of 
the ensuing biochemical cascades, but is generally 
described by the operational equation employed to fit the 25 
cytotoxicity data of Figure 3. It may be expected therefore 
that a regression of the spectral data against the 
physiological effect as expressed by the cell viability 
should yield a more precise result. However, it has been 
demonstrated for the case of low dose radiation responses 30 
in cellular systems, that the spectral responses are not 
linearly dependent on the physiological responses as 
measured by cytoxicological assays 41 Furthermore, it may 
be expected that the cascade of biochemical process 
introduces an increasing degree of variability into the 35 
measured response. In the development of spectroscopic  
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Figure 9: Calibration (A) and test set performance (B) in prediction with PLSR of the cell viability using Raman spectra of the cell membrane of A549 cells. 
The root mean squared errors of calibration (RMSEC) and prediction (RMSEP) are in the units of cell viability, which themselves are normalized to the level 
in the control. 
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Type of spectral data RMSEC RMSEP % error of prediction 
Target Conc. 
(µM) 
Viability Conc. 
(µM) 
Viability Conc. Viability 
Nucleus 1.7 (0.5) 0.05 (0.01) 3.4 (0.4) 0.11 (0.01) 6.8 
(0.8) 
11 
(1) 
Cytoplasm 1.5 (0.4) 0.07 (0.02) 3.7 (0.5) 0.14 (0.01) 7.5 
(0.9) 
14 
(1) 
Membrane 3.0 (0.3) 0.06 (0.02) 4.7 (0.5) 0.12 (0.01) 9.5 
(0.9) 
12 
(1) 
Combined data 6.4 (0.2) 0.15 (0.01) 8.2 (0.4) 0.19 (0.01) 16.3 
(0.9) 
19 
(1) 
 
 
 95 
 
 
techniques for biochemical and biomedical applications, 
the analysis of model systems such as the action of cis-
platin in vitro and comparison to parallel gold standard 100 
cytological assays is crucial. Ultimately, a more flexible 
nonlinear model is desirable, whereby the spectral data 
can be regressed against a user definable function. The 
results demonstrate Raman spectroscopy is a powerful 
tool to explore the molecular basis of the action of 105 
chemotherapeutic agents in vitro. As well as elucidating 
the mechanisms of interaction, the regression models can 
be employed in a predictive capacity. These findings also 
suggest that the technique should be applied to the 
spectral data from each component of the cell separately 110 
in order to increase the accuracy in the prediction of 
level of exposure and viability of the cell on the basis of 
the spectral changes. It should be noted that the cell 
Table 1: Prediction accuracies of the PLSR models based on the individual cellular components as well as the combined data, for regression against 
both the cisplatin dose and the cell viability. Figures in brackets denote standard deviations. 
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cultures were not synchronised according to cell cycle in 
this study. Synchronisation of the cells could be 
employed to further minimise the cellular variability, but 
also to explore the susceptibility of the cells to the drug 
as a function of cell cycle. 42, 43  5 
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